Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
CORTES, JORGE E
One or more keywords matched the following items that are connected to CORTES, JORGE E
Item TypeName
Academic Article Congestive heart failure is a rare event in patients receiving imatinib therapy.
Academic Article The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Academic Article Imatinib effect on growth and signal transduction in polycythemia vera.
Academic Article Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Concept Protein Kinase C
Concept Protein-Tyrosine Kinases
Concept Protein Kinase Inhibitors
Concept raf Kinases
Concept Receptor Protein-Tyrosine Kinases
Concept Mitogen-Activated Protein Kinase Kinases
Concept src-Family Kinases
Concept Protein Kinases
Concept Cyclin-Dependent Kinase 2
Concept Janus Kinase 1
Concept JNK Mitogen-Activated Protein Kinases
Concept Cyclin-Dependent Kinase Inhibitor p27
Concept Janus Kinase 2
Concept Phosphatidylinositol 3-Kinases
Concept Cyclin-Dependent Kinase Inhibitor p15
Concept Janus Kinases
Concept ZAP-70 Protein-Tyrosine Kinase
Concept Cyclin-Dependent Kinase Inhibitor p16
Concept fms-Like Tyrosine Kinase 3
Academic Article Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Academic Article Cardiovascular toxicity of tyrosine kinase inhibitors.
Academic Article The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.
Academic Article A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Academic Article Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Academic Article Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Academic Article Overcoming drug resistance in chronic myeloid leukemia.
Academic Article New strategies in chronic myeloid leukemia.
Academic Article Chronic myeloid leukemia: diagnosis and treatment.
Academic Article EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Academic Article Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Academic Article New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Academic Article Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Academic Article Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Academic Article WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Academic Article Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
Academic Article Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Academic Article Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Academic Article Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.
Academic Article Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.
Academic Article BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.
Academic Article Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
Academic Article Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Academic Article Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Academic Article Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Academic Article Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Academic Article Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Academic Article Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Academic Article Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Academic Article Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.
Academic Article Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
Academic Article Experimental therapeutics for patients with myeloproliferative neoplasias.
Academic Article Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Academic Article Competing cell clones in myeloproliferative neoplasm.
Academic Article Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia.
Academic Article Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.
Academic Article Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Academic Article Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
Academic Article Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
Academic Article Dasatinib for the treatment of chronic myeloid leukemia.
Academic Article Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Academic Article Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Academic Article Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
Academic Article Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
Academic Article Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
Academic Article Evolution of therapies for chronic myelogenous leukemia.
Academic Article Chronic myeloid leukemia: the race is yet to be won.
Academic Article Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Academic Article Treatment options for chronic myeloid leukemia.
Academic Article Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.
Academic Article Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Academic Article Current practices in the management of chronic myeloid leukemia.
Academic Article Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
Academic Article Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
Academic Article The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.
Academic Article Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Academic Article Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Academic Article Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Academic Article Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Academic Article Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Academic Article SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Academic Article Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.
Academic Article Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Academic Article Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Academic Article Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.
Academic Article Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Academic Article International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Academic Article Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Academic Article Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article Novel approaches in the treatment of systemic mastocytosis.
Academic Article The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Academic Article Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
Academic Article The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Academic Article Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Academic Article Sequencing of subcloned PCR products facilitates earlier detection of BCR-ABL1(T315I) and other mutants compared to direct sequencing of the ABL1 kinase domain.
Academic Article BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Academic Article Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Academic Article Management of patients with resistant or refractory chronic myelogenous leukemia.
Academic Article Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Academic Article The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Academic Article Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Academic Article Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Academic Article Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Academic Article Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
Academic Article Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Academic Article Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
Academic Article Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Academic Article Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
Academic Article Chronic myeloid leukemia: where do we go now?
Academic Article Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
Academic Article Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Academic Article Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Academic Article Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Academic Article Tyrosine kinase inhibitors: the first decade.
Academic Article Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
Academic Article Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Academic Article Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Academic Article The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
Academic Article Monitoring molecular response in chronic myeloid leukemia.
Academic Article Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Academic Article Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Academic Article Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.
Academic Article FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
Academic Article Mutant BCR-ABL clones in chronic myeloid leukemia.
Academic Article Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Academic Article Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Academic Article Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Academic Article Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Academic Article Chronic myeloid leukemia: mechanisms of resistance and treatment.
Academic Article Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Academic Article Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Academic Article Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Academic Article EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Academic Article Tyrosine kinase inhibitors in acute and chronic leukemias.
Academic Article Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Academic Article Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Academic Article Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Academic Article Bosutinib in the treatment of chronic myelogenous leukemia.
Academic Article Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
Academic Article Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
Academic Article Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Academic Article Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Academic Article Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
Academic Article Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a.
Academic Article A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.
Academic Article Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.
Academic Article PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Academic Article Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Academic Article Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
Academic Article Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.
Academic Article Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
Academic Article The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
Academic Article The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia.
Academic Article Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
Academic Article Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Academic Article Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Academic Article Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Academic Article Imatinib mesylate causes hypopigmentation in the skin.
Academic Article Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Academic Article Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Academic Article Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Academic Article The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Academic Article Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Academic Article Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Academic Article Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Academic Article Kinase inhibitors in chronic myelogenous leukemia.
Academic Article Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Academic Article Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
Academic Article The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors.
Academic Article MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Academic Article Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Academic Article Important therapeutic targets in chronic myelogenous leukemia.
Academic Article Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Academic Article Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Academic Article The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Academic Article Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Academic Article PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Academic Article Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Academic Article Flying under the radar: the new wave of BCR-ABL inhibitors.
Academic Article Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Academic Article Nilotinib therapy in chronic myelogenous leukemia.
Academic Article Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
Academic Article An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Academic Article Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Academic Article Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Academic Article Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Academic Article Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Academic Article Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
Academic Article Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Academic Article Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Academic Article Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
Academic Article Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
Academic Article Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Academic Article Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Academic Article Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Academic Article High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Academic Article The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Academic Article Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Academic Article Standard management of patients with chronic myeloid leukemia.
Academic Article Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Academic Article Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Academic Article Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Academic Article Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Academic Article Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
Academic Article Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).
Academic Article Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Academic Article Towards a cure for chronic myeloid leukemia: are we there yet?
Academic Article Third-generation tyrosine kinase inhibitors and beyond.
Academic Article Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Academic Article Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Academic Article Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Academic Article New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.
Academic Article Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
Academic Article Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Academic Article Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Academic Article Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Academic Article Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
Academic Article The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Academic Article The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Academic Article Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Academic Article Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Academic Article Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Academic Article Molecular targeted therapy in acute myeloid leukemia.
Academic Article Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia.
Academic Article Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.
Academic Article Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Academic Article The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era.
Academic Article Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Academic Article Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Academic Article Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Academic Article Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Academic Article Chronic myeloid leukemia: overview of new agents and comparative analysis.
Academic Article Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Academic Article Double-hit of FLT3 gene in a fatal case of acute myemonocytic leukaemia.
Academic Article The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.
Academic Article Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
Academic Article Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Academic Article Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
Academic Article KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Academic Article Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Academic Article A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Academic Article Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Academic Article Ponatinib in Philadelphia chromosome-positive leukemias.
Academic Article Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Academic Article BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Academic Article Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Academic Article Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.
Academic Article Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Academic Article Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Academic Article Biology of platelet-derived growth factor and its involvement in disease.
Academic Article Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Academic Article Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Academic Article Current and emerging treatment options in chronic myeloid leukemia.
Academic Article Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Academic Article Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Academic Article Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
Academic Article Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
Academic Article The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Academic Article A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
Academic Article Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Academic Article Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Academic Article First-line therapy for chronic myeloid leukemia: Past, present, and future.
Academic Article Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Academic Article Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Academic Article Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Academic Article Optimizing first-line therapy for patients with chronic myeloid leukemia.
Academic Article New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.
Academic Article Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Academic Article Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Academic Article Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Academic Article Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Academic Article Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
Academic Article Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.
Academic Article Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Academic Article Molecular resistance: an early indicator for treatment change?
Academic Article Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Academic Article Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.
Academic Article Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Academic Article FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article CML: the good, the better, and the difficult choices.
Academic Article The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
Academic Article Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Academic Article Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Academic Article BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Academic Article Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Academic Article Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Academic Article Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Academic Article Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Academic Article Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Academic Article Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Academic Article New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Academic Article Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Academic Article Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Academic Article Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Academic Article Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Academic Article Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Academic Article Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Academic Article Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Academic Article Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia.
Academic Article Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Academic Article Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Academic Article Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Academic Article Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Academic Article JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
Academic Article Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Academic Article Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature.
Academic Article Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
Academic Article Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Academic Article Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
Academic Article Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Academic Article Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.
Academic Article Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Academic Article Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Academic Article Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
Academic Article Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
Academic Article Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Academic Article Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
Academic Article BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.
Academic Article Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
Academic Article A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
Academic Article A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
Academic Article Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Academic Article The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Academic Article Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Academic Article A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
Academic Article Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
Academic Article Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Academic Article Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Academic Article Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Academic Article Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Academic Article Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
Academic Article Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Academic Article Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.
Academic Article Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Academic Article Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.
Academic Article Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Academic Article Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors
Academic Article Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia
Academic Article Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors
Academic Article Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Academic Article Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Academic Article KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies
Academic Article Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Academic Article Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia-a propensity score analysis
Academic Article Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Academic Article New tyrosine kinase inhibitors in chronic myeloid leukemia (CML)
Academic Article Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Academic Article Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Academic Article Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
Academic Article Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
Academic Article Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
Academic Article Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
Academic Article Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Academic Article Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Academic Article Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Academic Article Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Academic Article Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.
Academic Article Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Academic Article Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Academic Article Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Academic Article Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
Academic Article Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.
Academic Article Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
Academic Article KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Academic Article Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
Academic Article Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Academic Article Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Academic Article Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].
Academic Article Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Academic Article Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
Academic Article Reply to K.R. Hoffman.
Academic Article Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Academic Article First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Academic Article Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Academic Article Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
Academic Article Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Academic Article Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Academic Article Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
Academic Article A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
Academic Article Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
Academic Article Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Academic Article Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
Academic Article A second-generation TKI should always be used as initial therapy for CML.
Academic Article Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Academic Article Tyrosine Kinase Inhibitor-associated Fibrothorax.
Academic Article Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Concept Checkpoint Kinase 1
Concept TOR Serine-Threonine Kinases
Academic Article Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Academic Article Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Academic Article Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Academic Article Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Academic Article Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Academic Article Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Academic Article Treatment-free remission in chronic myeloid leukemia.
Academic Article Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Academic Article Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
Academic Article Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
Academic Article Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
Academic Article Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
Academic Article Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
Academic Article Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Academic Article The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes.
Academic Article Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
Academic Article Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Academic Article Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Academic Article A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Academic Article A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Academic Article Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
Academic Article Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.
Academic Article Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Academic Article A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
Academic Article Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
Academic Article Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Academic Article Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Academic Article Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
Academic Article Health care resource utilization in 3L?+?patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.
Academic Article Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
Search Criteria
  • Phosphotransferases